adapalene; benzoyl peroxide; clindamycin phosphate · Bausch · NDA 216632
Cabtreo
Earliest generic entry, as listed
28 Dec 2040
Blocked by patent: US 11389467.
Listed patents · 9 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11389467 | product, use U-3713 | 28 Dec 2040 |
| US 12128059 | product, use U-3713 | 31 Jul 2040 |
| US 12133859 | product | 31 Jul 2040 |
| US 12138278 | product | 31 Jul 2040 |
| US 12616710 | product | 31 Jul 2040 |
| US 8288434 | product, use U-3713 | 5 Aug 2029 |
| US 10220049 | product, use U-3713 | 3 Jun 2029 |
| US 10624918 | use U-3713 | 3 Jun 2029 |
| US 9561208 | product, use U-3713 | 3 Jun 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 216632 · 001 · RLD | gel, topical | 0.15%;3.1%;1.2% | 28 Dec 2040 |
Expired or delisted (1)
- NP · 20 Oct 2026